Embelin as a Promising Therapeutic Agent: Current Advances and Future Perspectives

Abstract

Embelin, which is derived from plants belonging to the genus Embelia, most eminently Embelia ribes Burm. has been respected in conventional medicinal practices for quite a while due to the pharmacological properties that it possesses. These properties are essentially a result of the element hydroxyl benzoquinone that it contains. A lot of interest in its possible therapeutic applications, outstandingly in the treatment of cancer, has been ignited as a result of its recent discovery as a non-peptidic, cell-permeable inhibitor of the X-linked inhibitor of apoptosis protein (XIAP). As a potential anticancer medication, Embelin demonstrates a promising profile by demonstrating a range of anticancer mechanisms across a variety of cancer types. These mechanisms include the acceptance of apoptosis, the arrest of the cell cycle, and autophagy creation. The control of significant sign transduction pathways, like NF-κB, PI3Kinase/AKT, and STAT3, further demonstrates the effectiveness of this compound in preventing the development of several cancer cell lines. The purpose of this extensive literature review is to give a detailed investigation of the anticancer potential of Embelin, explaining its mechanisms of activity and featuring potential clinical uses. Besides the fact that this review features recent advancements, yet it additionally provides clever perspectives into the future trajectory of Embelin-based therapies, thereby pushing for continued research and clinical interpretation in the field of cancer therapeutics. This review draws upon relevant scientific literature from the previous decade that was sourced from a variety of electronic databases.